| Trial ID: | L6603 |
| Source ID: | NCT00908271
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: Absolute oral bioavailability, Within the 3 days after study drug administration | Secondary: Adverse events (AE), Within the 3 days after study drug administration|Vital signs, Within the 3 days after study drug administration|Clinical safety labs, Within the 3 days after study drug administration|Electrocardiograms (ECGs), Within the 3 days after study drug administration
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Bristol-Myers Squibb
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
7
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:
|
| Start Date: |
2009-07
|
| Completion Date: |
2009-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-17
|
| Locations: |
Covance Clinical Research Unit, Inc., Madison, Wisconsin, 53704, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00908271
|
